Piper Sandler Cuts Humacyte (NASDAQ:HUMA) Price Target to $2.75

Humacyte (NASDAQ:HUMAGet Rating) had its price target reduced by Piper Sandler from $3.50 to $2.75 in a research note released on Thursday, The Fly reports.

Separately, BTIG Research decreased their target price on Humacyte to $9.00 in a research report on Thursday, October 20th.

Humacyte Stock Down 1.5 %

Shares of HUMA stock opened at $3.21 on Thursday. Humacyte has a 1 year low of $3.02 and a 1 year high of $12.22. The stock has a market cap of $330.65 million, a PE ratio of 10.03 and a beta of 1.01. The business’s fifty day moving average is $3.55 and its 200-day moving average is $4.07. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.46 and a current ratio of 17.46.

Humacyte (NASDAQ:HUMAGet Rating) last issued its quarterly earnings results on Friday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.03. Humacyte had a negative return on equity of 73.96% and a net margin of 1,971.30%. The company had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $0.27 million. Equities analysts expect that Humacyte will post -0.84 earnings per share for the current fiscal year.

Insider Transactions at Humacyte

In other news, Director Brady W. Dougan sold 1,522,500 shares of the firm’s stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $4.00, for a total value of $6,090,000.00. Following the completion of the sale, the director now owns 18,930,004 shares of the company’s stock, valued at $75,720,016. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 25.00% of the stock is currently owned by insiders.

Institutional Trading of Humacyte

A number of institutional investors have recently bought and sold shares of the company. UBS Group AG boosted its position in Humacyte by 92.0% during the third quarter. UBS Group AG now owns 9,827 shares of the company’s stock valued at $32,000 after purchasing an additional 4,710 shares during the last quarter. Hamilton Lane Advisors LLC acquired a new stake in Humacyte during the third quarter valued at $172,000. Teacher Retirement System of Texas acquired a new stake in Humacyte during the third quarter valued at $60,000. SG Americas Securities LLC acquired a new stake in Humacyte during the third quarter valued at $35,000. Finally, Legal & General Group Plc boosted its position in Humacyte by 24.7% during the second quarter. Legal & General Group Plc now owns 16,970 shares of the company’s stock valued at $55,000 after purchasing an additional 3,364 shares during the last quarter. Institutional investors and hedge funds own 13.05% of the company’s stock.

About Humacyte

(Get Rating)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).

See Also

The Fly logo

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.